XNCR
XNCR clinical trials: Xencor Inc
Every trial on ClinicalTrials.gov where Xencor Inc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 35
- Trials linked
- 30
- As lead sponsor
- 5
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
XNCR on the catalyst calendar · XNCR registry changes
- Primary completion Aug 2027Sponsor estimatePhase 1NCT07713485Study of XmAb412 in Healthy ParticipantsXencor, Inc. · Not Applicable - Healthy Adult ParticipantsRecruitingXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1/Phase 2NCT06619990Study of XmAb942 in Healthy Participants and Participants With Ulcerative ColitisXencor, Inc. · Ulcerative Colitis (UC)RecruitingXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1NCT06276491Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid TumorsXencor, Inc. · Ovarian CancerRecruitingXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 1NCT07593092Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid TumorsXencor, Inc. · Ovarian CancerRecruitingXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2028Sponsor estimatePhase 1NCT07284797A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune DiseasesXencor, Inc. · HealthyRecruitingXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 1NCT07230353A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid ArthritisXencor, Inc. · Rheumatoid ArthritisRecruitingXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2027Sponsor estimatePhase 1NCT05433142Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaXencor, Inc. · Clear Cell Renal Cell CarcinomaRecruitingXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 10, 2025ActualPhase 2NCT05005728XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant...Xencor, Inc. · Metastatic Castration-Resistant Prostate CancerCompletedXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 24, 2025ActualPhase 1/Phase 2NCT06173505Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLCXencor, Inc. · Nonsquamous Non-small Cell Lung CancerTerminatedXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 22, 2024ActualPhase 1NCT06005792Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic DermatitisXencor, Inc. · PsoriasisTerminatedXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 20, 2025ActualPhase 1NCT05585034Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsXencor, Inc. · Head and Neck Squamous Cell CarcinomaCompletedXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2025Sponsor estimatePhase 2NCT05032040A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesXencor, Inc. · Ovarian CancerActive, not recruitingXNCRLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2024ActualPhase 1NCT02924402Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesXencor, Inc. · B-cell Non-Hodgkins LymphomaCompletedXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 21, 2024ActualPhase 1NCT05996445A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid TumorsXencor, Inc. · Solid TumorsTerminatedXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 15, 2024ActualPhase 1NCT03752398A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)Xencor, Inc. · Melanoma (Excluding Uveal Melanoma)CompletedXNCRLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 21, 2023ActualPhase 2NCT05328102Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory...Xencor, Inc. · Diffuse Large-cell B-cell LymphomaTerminatedXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 24, 2022ActualPhase 1/Phase 2NCT04590781Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung CancerXencor, Inc. · Merkel Cell CarcinomaTerminatedXNCRLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 16, 2023ActualPhase 1NCT03849469A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsXencor, Inc. · MelanomaCompletedXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 19, 2020ActualPhase 1NCT03445663Study Evaluating AMG 424 in Subjects With Multiple MyelomaXencor, Inc. · Relapsed/ Refractory Multiple MyelomaTerminatedXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 10, 2022ActualPhase 1NCT04857866Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy VolunteersXencor, Inc. · Safety in Healthy VolunteersCompletedXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2022ActualPhase 1NCT03517488A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsXencor, Inc. · MelanomaCompletedXNCRLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 26, 2021ActualPhase 1NCT03411915A Study of XmAb®18087 in Subjects With NET and GISTXencor, Inc. · Neuroendocrine TumorCompletedXNCRLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2021ActualPhase 1NCT02730312PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic MalignanciesXencor, Inc. · Acute Myelogenous LeukemiaCompletedXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 17, 2018ActualPhase 2NCT02725515A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus ErythematosusXencor, Inc. · Systemic Lupus ErythematosusCompletedXNCRLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2017ActualPhase 2NCT02725476Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)Xencor, Inc. · IgG4-RDCompletedXNCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 10 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner